Unlock instant, AI-driven research and patent intelligence for your innovation.

Treatment of inflammatory diseases with inhibitors of c5a activity

A technology for inflammatory diseases and inhibitors, applied in the field of C5a activity inhibitors, can solve the problems of host organ immune attack, differentiation defects, self-molecules and tissues improperly recognized as foreign structures, etc.

Pending Publication Date: 2020-05-05
INFLARX
View PDF16 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0026] Autoimmune diseases are defined as defective differentiation of self and nonself molecules, resulting in inappropriate recognition of self molecules and tissues as foreign structures, accompanied by immune attack on host organs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of inflammatory diseases with inhibitors of c5a activity
  • Treatment of inflammatory diseases with inhibitors of c5a activity
  • Treatment of inflammatory diseases with inhibitors of c5a activity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0112] The present invention will now be further described. In the following paragraphs, different aspects of the invention are defined in more detail. Each aspect defined below may be combined with one or more than one other aspect unless clearly stated to the contrary. In particular, any feature indicated as preferred or advantageous may be combined with any other feature indicated as preferred or advantageous.

[0113] In a first aspect, the present invention relates to a compound for use in the treatment of a cutaneous neutrophil inflammatory disease in a subject, wherein said compound is an inhibitor of C5a activity, and wherein said cutaneous neutrophil inflammatory disease The disease is selected from the group consisting of hidradenitis suppurativa (HS); pyoderma gangrenosum (PG); PAPA (septic arthritis, PG, and acne); PASH (PG, acne, and hidradenitis suppurativa); inflammation, acne, PG, and hidradenitis suppurativa); Sweet syndrome (SS); subcorneal pustular dermato...

Embodiment

[0247] The following examples are provided to further illustrate the invention. However, the present invention is not limited thereto, and the following examples merely show the practicability of the present invention based on the above description.

[0248] 1. Method

[0249] 1.1 Preparation of zymosan A stock solution and activated plasma

[0250] Dissolve Zymosan A to 2 mg / ml in 50 ml sterile saline and boil at 100°C for 1 hour. After centrifugation, discard the supernatant and resuspend the pellet in 50 ml sterile saline. After the second centrifugation step, the pellet was resuspended in 5 ml sterile saline to obtain a 20 mg / ml stock solution. Aliquot the stock solution and store at -20 °C until use. To activate plasma, Zymosan A stock solution and 100 μl plasma were mixed and incubated at 37 °C for 30 min. After incubation, the tubes were centrifuged and the supernatant was aliquoted and stored at -20°C until use.

[0251] 1.2 CD11b assay using rhC5a or ZAP as ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.

Description

technical field [0001] The present invention relates to a C5a activity inhibitor and its use in treating skin neutrophil inflammatory disease of a subject. [0002] Background of the invention [0003] Target C5a in inflammation [0004] C5a is a cleavage product of the 74 amino acid span of its "parent molecule" C5, and represents one terminus of the complement activation cascade. It can be produced by activation of at least three well-described pathways (alternative, classical and MBL pathways). All pathways fuse at the C3 level to form a C5 convertase or an alternative C5 convertase that cleaves C5 into C5a and C5b. The latter binds to C6, C7, C8 and multiple C9 molecules, ultimately leading to the formation of pores in eg bacterial membranes (terminal membrane attack complex = MAC). C5a is produced when the complement system is activated in conditions of inflammation and other immune and inflammatory conditions / diseases. [0005] Among complement activation products, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/18A61P17/10
CPCC07K16/18A61K2039/505C07K2317/76A61P17/00A61P17/10A61P29/00A61P37/02A61K31/711C07K2317/24A61K39/3955C07K16/2896A61K47/6807C07K2317/55C07K16/40
Inventor 郭仁峰尼尔斯·C·里德曼
Owner INFLARX